mCRC
FDA Grants Accelerated Approval to Braftovi for Some Patients With Metastatic Colorectal Cancer
The FDA granted accelerated approval to Braftovi with cetuximab and mFOLFOX6 for patients with metastatic ...
JANUARY 2, 2025
Erbitux Every 2 Weeks as Effective as Weekly
Data from a recent analysis confirmed the efficacy of a regimen of 500 mg/m2 of cetuximab every two weeks ...
MAY 19, 2021
New Dosing Regimen Approved for Erbitux
The FDA approved a regimen of 500 mg/m2 of cetuximab (Erbitux, ImClone) given intravenously over 120 minutes every ...
APRIL 9, 2021
FDA Grants New Indication for Opdivo + Yervoy Combo in mCRC
The FDA granted a new indication for Opdivo and Yervoy to treat adults and children 12 years of age and older with ...
JULY 12, 2018
Load more